2. Metabolic Enzyme/Protease
  3. Phosphatase
  4. Neridronate

Neridronate is an aminobisphosphonate. Neridronate induces osteoblast differentiation, enhances alkaline phosphatase activity and mineralized nodule formation. Neridronate inhibits endothelial cell proliferation, fibroblast growth factor-2-induced capillary-like tube formation, and angiogenesis. Neridronate can be used for osteogenesis imperfecta and Paget’s disease of bone.

Para uso exclusivo en investigación. No vendemos a pacientes.

Neridronate

Neridronate Estructura química

No. CAS : 79778-41-9

Tamaño Precio Stock Cantidad
5 mg En stock
10 mg En stock
25 mg En stock
50 mg En stock
100 mg En stock
200 mg   Obtener un presupuesto  
500 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 1 Customer Validation

Other Forms of Neridronate:

Neridronate Related Antibodies

Top Publications Citing Use of Products

  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

Neridronate is an aminobisphosphonate. Neridronate induces osteoblast differentiation, enhances alkaline phosphatase activity and mineralized nodule formation. Neridronate inhibits endothelial cell proliferation, fibroblast growth factor-2-induced capillary-like tube formation, and angiogenesis. Neridronate can be used for osteogenesis imperfecta and Paget’s disease of bone[1][2][3].

Cellular Effect
Cell Line Type Value Description References
T-cell IC50
1.96 3
Compound: 45
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release
[PMID: 14711309]
HFF IC50
59.7 3
Compound: 34
In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)
In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)
[PMID: 15857119]
T-cell IC50
503 3
Compound: 45
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL
[PMID: 14711309]
T-cell IC50
503 3
Compound: 45
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL
[PMID: 14711309]
HFF IC50
59.7 3
Compound: 34
In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)
In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)
[PMID: 15857119]
T-cell IC50
1.96 3
Compound: 45
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release
[PMID: 14711309]
Vero IC50
>200 3
Compound: 10
Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum
Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum
[PMID: 11300872]
T-cell IC50
1.96 3
Compound: 45
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release
[PMID: 14711309]
T-cell IC50
503 3
Compound: 45
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL
Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL
[PMID: 14711309]
Vero IC50
> 200 3
Compound: 10
Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum
Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum
[PMID: 11300872]
In Vitro

Neridronate (≤10-8-10-3 M; 0-20 days) at 10-3 M causes cytotoxicity and cell death in primary human osteoblasts grown in 10% FCS over 20 days, 10-4 M inhibits proliferation, 10-5 to 10-7 M increases viable cell counts, and concentrations ≤10-8 M have no effect on viability or proliferation[1].
Neridronate (10-7-10-4 M; 4-8 days) at 10-5 to 10-7 M increases type I collagen synthesis in primary human osteoblasts grown in 10% FCS after 4 days, while 10-4 to 10-6 M reduces synthesis after 8 days[1].
Neridronate (10-8-10-7 M; 10-20 days) at 10-8 M maximally increases ALKP activity by 50% in primary human osteoblasts grown in 10% FCS after 10 days, and 10-7 M increases activity by 22% after 20 days[1].
Neridronate (10-8-10-4 M; 4-20 days) at 10-4 M increases mineralized nodule formation in primary human osteoblasts grown in 2% UG after 4 days, while 10-7 and 10-8 M increase formation by 44% and 24%, respectively, after 20 days[1].
Neridronate (1-50 μM; 24 h) dose-dependently inhibits the proliferation of human umbilical vein endothelial cells, with peak activity at 30 μM after 24 h of treatment[2].
Neridronate (30 μM; 18 h) disrupts FGF-2-induced capillary-like tube formation by human umbilical vein endothelial cells seeded on Matrigel after 18 h of incubation[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Neridronate Related Antibodies

Cell Proliferation Assay[2]

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 1 μM, 3 μM, 10 μM, 30 μM, 50 μM
Incubation Time: 24 h
Result: Reduced HUVEC growth in a dose-dependent fashion, with peak inhibition at 30 μM; 50 μM produced a plateau effect.
Showed statistically significant inhibition at 10 μM, 30 μM, and 50 μM.
In Vivo

Neridronate (50 μM/embryo; via gelatin sponge on CAM; single administration on day 8 of incubation) significantly reduces FGF-2-induced angiogenesis in the chick embryo CAM assay[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: White Leghorn (fertilized eggs)[2]
Dosage: 50 μM/embryo
Administration: via gelatin sponge on CAM; single administration on day 8 of incubation
Result: Reduced the mean number of FGF-2-induced blood vessels entering the sponge to 15 ± 3 (compared to 30 ± 4 for FGF-2 alone).
Ensayo clínico
Peso molecular

277.15

Fòrmula

C6H17NO7P2
No. CAS
Appearance

Solid

Color

White to off-white

SMILES

OC(P(O)(O)=O)(CCCCCN)P(O)(O)=O
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvente y solubilidad
In Vitro: 

H2O : 5 mg/mL (18.04 mM; ultrasonic and warming and adjust pH to 8 with NaOH and heat to 60°C)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.6082 mL 18.0408 mL 36.0815 mL
5 mM 0.7216 mL 3.6082 mL 7.2163 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Calculadora de molaridad

  • Calculadora de dilución

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 2 mg/mL (7.22 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Pureza y Documentación

Purity: 98.0%

SDS (393 KB)

COA (247 KB) HNMR (258 KB)

Instrucciones de manejo (2659 KB)
Referencias

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 3.6082 mL 18.0408 mL 36.0815 mL 90.2039 mL
5 mM 0.7216 mL 3.6082 mL 7.2163 mL 18.0408 mL
10 mM 0.3608 mL 1.8041 mL 3.6082 mL 9.0204 mL
15 mM 0.2405 mL 1.2027 mL 2.4054 mL 6.0136 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Neridronate Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Neridronate79778-41-9Phosphataseangiogenesishuman osteoblastsmultiple myeloma bone lesionshuman umbilical vein endothelial cellschick embryo CAM assayosteoporosisfibroblast growth factor-2Paget’s disease of boneosteogenesis imperfectaendothelial cell proliferationInhibitorinhibitorinhibit

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

  

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

      

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
Neridronate
Cat. No.:
HY-119443
Cantidad:
MCE Japan Authorized Agent:

Revisión del cliente

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nombre del producto

  

Lot #

Nombre del solicitante *

 

Direcciòn del E-mail *

Número de teléfono

 

Department *

Nombre de la Organizaciòn *

 

Country or Region *

Observaciones

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.